Summit Corporation PLC

Type: Company
Name: Summit Corporation PLC
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Summit Corporation PLC : Summit Corporation PLC : Notice of Results

Summit Corporation plc('Summit' or the 'Company')NOTICE OF INTERIM RESULTSOxford, UK, 1 September 2014 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, will ... [Published Investegate - 7 hours ago]
First reported Aug 07 2014 - Updated Aug 07 2014 - 2 reports

Summit Corporation PLC : Summit to Present at the Canaccord Genuity 34th...

Summit Corporation plc('Summit' or the 'Company')SUMMIT TO PRESENT COMPANY OVERVIEW AT THE CANACCORD GENUITY 34TH ANNUAL GROWTH CONFERENCEOxford, UK, 7 August 2014 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for ... [Published Investegate - Aug 07 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Research and Markets Adds Report: 'Plague - Pipeline Review, H1 2014'

Research and Markets announced the addition of the "Plague - Pipeline Review, H1 2014" report to its offerings. In a release, Research and Markets noted that report highlights include:This report provides comprehensive information on the therapeutic development ... [Published Individual.com - Aug 04 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 3 reports

Summit chief buys 30,000 shares

AIM-listed drug developer Summit, which develops therapies for Duchenne Muscular Dystrophy and C. difficile infection, on Wednesday said its chief executive Glyn Edwards had acquired 30,000 shares.The 104.5p-a-share deal cost Edwards £31,350 and took ... [Published London South East - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Summit Corporation climbs as CEO ups stake

Shares in drug discovery firm Summit ( LON:SUMM ) advanced early on Wednesday as it emerged chief executive Glyn Edwards has upped his stake. Edwards bought 30,000 shares at 104.5p a pop, taking his holding to 233,333 shares, representing 0.57% of the ... [Published Proactiveinvestors United Kingdom RSS feed - Jul 30 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Proactive news summary - Roxi Petroleum, Mwana Africa, Ortac, Sula Iron & Gold, Iofina, Summit Corp, Alliance Pharma, Ascent Resources, Providence, Victoria Oil & Gas

Roxi Petroleum ( LON:RXP ) virtually doubled in price after news of a discovery at its flagship BNG asset in Kazakhstan. Results from Mwana Africa ( LON:MWA ) got the thumbs-up early on though gains  were clawed back later. Underlying earnings (EBITDA) ... [Published Proactiveinvestors United Kingdom RSS feed - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 2 reports

UPDATE - Summit Corp antibiotic could be fast-tracked under American initiative

---ADDS BROKER COMMENT AND SHARE PRICE--- Summit Corp’s ( LON:SUMM ) drug candidate for C. difficile infection has been accepted to a US initiative designed to speed up the development of new antibiotics. The AIM-listed group’s SMT19969 has been designated ... [Published Proactiveinvestors United Kingdom RSS feed - Jul 09 2014]
First reported May 21 2014 - Updated May 21 2014 - 1 reports

Proactive news summary including Sea Energy, Summit Corp, DekelOil, Northcote Energy and OPG Power Ventures

SeaEnergy ( LON:SEA ) shares went over 8% as its recently established subsidiary SeaEnergy Ship Management (SEASM) was awarded its first ship management contract. The SEASM team will be responsible for the management of the crew, provisions and technical ... [Published Proactiveinvestors United Kingdom RSS feed - May 21 2014]
First reported May 21 2014 - Updated May 21 2014 - 1 reports

Summit’s Pye talks about encouraging trial results

Richard Pye, Summit Corporation’s ( LON:SUMM ) director of corporate communications, says the company is encouraged by early signs that its treatment for DMD is working. It follows preliminary results from a phase 1b trial of SMT C1100 in 12 boys, who ... [Published Proactiveinvestors United Kingdom RSS feed - May 21 2014]
First reported May 12 2014 - Updated May 12 2014 - 3 reports

FTSE 100 ends Monday higher thanks to miners and drug M&A

London’s blue-chips closed Monday around a half percent better, as blue-chip mining stocks helped sentiment. By the close, the FTSE 100 index was 37 points, 0.55%, higher – changing hands at around 6,851. Takeovers in the drug business also continue ... [Published Proactiveinvestors United Kingdom website - May 12 2014]
First reported May 12 2014 - Updated May 12 2014 - 1 reports

Summit study points to C.difficile drug's efficacy alongside frontline treatments

Drug developer Summit Corp ( LON:SUMM ) said “exciting” results in non-clinical tests of SMT 19969 for C. difficile infection (CDI) point to its potential efficacy alongside the two current frontline treatments.  An in-vivo study revealed the three ... [Published Proactiveinvestors United Kingdom RSS feed - May 12 2014]
First reported Apr 30 2014 - Updated Apr 30 2014 - 1 reports

Summit Corp financially well set to progress lead drugs

Summit Corp’s ( LON:SUMM ) full-year results chart the significant progress of the drug development group. In December its potentially breakthrough treatment for the fatal wasting disease Duchenne Muscular Dystrophy enrolled its first patients onto ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 30 2014]

Quotes

...(AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C difficile infection ( "CDI'), announces that it will be presenting at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014, at 16:00 ET (21:00 BST). The conference will be held at the InterContinental Boston Hotel in Boston, MA. Mr Glyn Edwards, Summit's Chief Executive Officer, will present a review of the Company's utrophin modulation programme for the treatment of the fatal muscle wasting disease DMD and he will also review Summit's selective antibiotic in development for the treatment of CDI. A copy of the presentation will be available immediately after the event on the Investor Relations section of the Company's website, www.summitplc.com. - END - Notes to Editors About Summit Summit is an Oxford, UK based drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C difficile infection. Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc https://twitter.com/Summitplc ). For more information, please contact: Summit Tel: +44 (0)1235 443 939 Glyn Edwards / Richard Pye Cairn Financial Advisers LLP Tel: +44 (0)20 7148 7900 (Nominated Adviser) Liam Murray / Tony Rawlinson N+1 Singer Tel: +44 (0)20 7496 3000 (Broker) Aubrey Powell / Jen Boorer Peckwater PR (Financial public relations, UK) Tel: +44 (0)7879 458 364 Tarquin Edwards tarquin.edwards@peckwaterpr.co.uk MacDougall Biomedical Communications Tel: +1 781-235-3060 (US media contact) mavery@macbiocom.com Michelle Avery This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Summit Corporation PLC via Globenewswire HUG#1847074 http://www.summitplc.com/"
...that, on 29 July 2014, Glyn Edwards, Chief Executive Officer of the Company, acquired 30,000 ordinary shares of 1 penny each ("Ordinary Shares ") in the Company at a price of 104.5 pence per Ordinary Share."
Chief executive Edwards told investors: "This status recognises the serious healthcare threat posed by pathogens such as C difficile and it will confer a number of advantages that will accelerate the development of this promising and differentiated antibiotic with the potential to treat initial CDI and reduce the high rates of disease recurrence, the major clinical issue."
Chairman Frank Armstrong said: "With the funds secured from investors, charitable foundations and the UKUK government, Summit is now well placed to execute our future clinical plans that seek to establish the potential of our two programmes as potential life-changing treatments for two serious diseases."

More Content

All (26) | News (24) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Summit Corporation PLC : Summit Corporation PLC... [Published Investegate - 7 hours ago]
Summit Corporation PLC : Summit to Present at t... [Published Investegate - Aug 07 2014]
Summit Corporation PLC Summit To Present At The... [Published ADVFN UK - Aug 07 2014]
Research and Markets Adds Report: 'Plague - Pip... [Published Individual.com - Aug 04 2014]
Summit chief buys 30,000 shares [Published London South East - Jul 30 2014]
Summit Corporation climbs as CEO ups stake [Published Proactiveinvestors United Kingdom RSS feed - Jul 30 2014]
Summit Corporation PLC : Director/PDMR Sharehol... [Published Investegate - Jul 30 2014]
REG-Director/PDMR Shareholding [Published Reuters - Jul 30 2014]
Research breakthroughs and deal speculation put... [Published Proactiveinvestors United Kingdom RSS feed - Jul 12 2014]
Proactive news summary - Roxi Petroleum, Mwana ... [Published Proactiveinvestors United Kingdom RSS feed - Jul 09 2014]
UPDATE - Summit Corp antibiotic could be fast-t... [Published Proactiveinvestors United Kingdom RSS feed - Jul 09 2014]
Summit Corp antibiotic could be fast-tracked un... [Published Proactiveinvestors United Kingdom RSS feed - Jul 09 2014]
Market Report: Investors back Shire deal [Published The Independent - Jun 17 2014]
Proactive news summary including Sea Energy, Su... [Published Proactiveinvestors United Kingdom RSS feed - May 21 2014]
Summit’s Pye talks about encouraging trial results [Published Proactiveinvestors United Kingdom RSS feed - May 21 2014]
FTSE 100 ends Monday higher thanks to miners an... [Published Proactiveinvestors United Kingdom website - May 12 2014]
FTSE 100 edges forward thanks to miners and dru... [Published Proactiveinvestors United Kingdom RSS feed - May 12 2014]
Monday's movers including Leni Gas & Oil, Strat... [Published Proactiveinvestors United Kingdom RSS feed - May 12 2014]
Summit study points to C.difficile drug's effic... [Published Proactiveinvestors United Kingdom RSS feed - May 12 2014]
Summit Corp financially well set to progress le... [Published Proactiveinvestors United Kingdom RSS feed - Apr 30 2014]
FTSE 100 flat as attentions turn to pre-budget ... [Published Proactiveinvestors United Kingdom RSS feed - Mar 18 2014]
Market movers: ASOS, Sainsbury’s, Antofagasta, ... [Published Proactiveinvestors United Kingdom RSS feed - Mar 18 2014]
Summit primed for positive momentum - N+1 Singer [Published Proactiveinvestors United Kingdom RSS feed - Mar 11 2014]
Are European investors falling in love with bio... [Published Proactiveinvestors United Kingdom website - Feb 14 2014]
Summit fundraise will leave it in "really good ... [Published Proactiveinvestors United Kingdom RSS feed - Feb 12 2014]
AIM Notice - 29/11/2013 [Published TrustNet - Nov 29 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FTSE 100 ends Monday higher thanks to miners an... [Published Proactiveinvestors United Kingdom website - May 12 2014]
London’s blue-chips closed Monday around a half percent better, as blue-chip mining stocks helped sentiment. By the close, the FTSE 100 index was 37 points, 0.55%, higher – changing hands at around 6,851. Takeovers in the drug business also continue ...
Are European investors falling in love with bio... [Published Proactiveinvestors United Kingdom website - Feb 14 2014]
America’s love affair with biotechnology is well charted. In the last three years it has been the best performing investment sector, supported by the success of smaller research-led firms and the continued growth of some of the industry’s bigger hitters. ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.